Quark’s RNAi treatment misses the mark in a Phase II kidney trial

Damian Garde

Quark Pharmaceuticals' gene-silencing for transplant complications missed its primary endpoint in a II , possibly jeopardizing a deal with Novartis worth up to $ 680 million.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS